The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study
Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.
Estimation of the number of RSV-associated hospitalisations in adults in the European Union
RSV is a major cause of lower respiratory tract infections in older adults. Estimating RSV- associated hospitalisation is critical for planning RSV-related healthcare needs for the ageing population across Europe.
News
Reports
Policy & Recommendations
Policy priorities for protecting adults at risk of severe illness from RSV
IFA participated in the generation of a new report by the Health Policy Partnership to build awareness of the impact of RSV in adults and highlight opportunities to reduce its burden on society through appropriate prevention, diagnosis, and care.
|
ESWI Airborne: Meet the Members
Celebrating ESWI 30 years!
Who would have taken virus isolation for granted 30 years ago? How and why did ESWI transform from a pure virology-based network to one encompassing a public health perspective?
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults.
The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design
After a 1960s RSV vaccine was found to enhance disease in previously unexposed infants, development was put on hold. But structure-based design has led to effective RSV vaccines that now await approval.
European Parliament sets up new Public Health subcommittee
The subcommittee will deal with programmes and specific actions in the field of public health, pharmaceutical and cosmetic products, health aspects of bioterrorism, the European Medicines Agency, and the European Centre for Disease Prevention and Control.
Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study
RSV infections cause an estimated 22-50 million episodes of acute lower respiratory infections (ALRI) every year in children younger than 5 years.
Healthcare facilities should maintain and strengthen infection prevention and control measures during peaks of respiratory viruses transmission
ECDC recommends that healthcare facilities maintain and strengthen infection prevention and control measures, due to the high community transmission and co-circulation of respiratory viruses such as SARS-CoV-2, influenza, RSV and others.
Respiratory viruses and infection control
Health Europa spoke to Dr Albert Osterhaus about the burden of respiratory infections.
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
RSV infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection.
